{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:37:19Z","timestamp":1791463039965,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","award":["MRC-RFA-UFSP-01-2013\/UKZN HIVEPI"],"award-info":[{"award-number":["MRC-RFA-UFSP-01-2013\/UKZN HIVEPI"]}],"id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2019CDF-2728"],"award-info":[{"award-number":["TMA2019CDF-2728"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004695","name":"Inyuvesi Yakwazulu-Natali","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010753","name":"National Health Laboratory Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010753","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2021.10.023","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T01:28:15Z","timestamp":1636853295000},"page":"468-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-4531","authenticated-orcid":false,"given":"Benjamin","family":"Chimukangara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0926-710X","authenticated-orcid":false,"given":"Richard J.","family":"Lessells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benn","family":"Sartorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1060-9170","authenticated-orcid":false,"given":"Lilishia","family":"Gounder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0680-7337","authenticated-orcid":false,"given":"Sontaga","family":"Manyana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melendhran","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1726-4454","authenticated-orcid":false,"given":"Lavanya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-4583","authenticated-orcid":false,"given":"Jennifer","family":"Giandhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerusha","family":"Govender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-6084","authenticated-orcid":false,"given":"Reshmi","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nokukhanya","family":"Msomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8874-6661","authenticated-orcid":false,"given":"Kogieleum","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulio","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9946-8783","authenticated-orcid":false,"given":"Pravi","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-1011","authenticated-orcid":false,"given":"Raveen","family":"Parboosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.10.023_bib0001","series-title":"Global action plan on HIV drug resistance 2017\u20132021","year":"2017"},{"key":"10.1016\/j.jgar.2021.10.023_bib0002","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in sub-Saharan Africa","volume":"215","author":"Phillips","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0003","unstructured":"Naidoo K. The Advanced Clinical Care (ACC) Program in KwaZulu-Natal.2016. https:\/\/za.usembassy.gov\/wp-content\/uploads\/sites\/19\/2016\/06\/The-Advanced-Clinical-Care-Program-in-KZN_Kogie-Naidoo.pdf [accessed 1 February 2021]."},{"key":"10.1016\/j.jgar.2021.10.023_bib0004","doi-asserted-by":"crossref","first-page":"e72152","DOI":"10.1371\/journal.pone.0072152","article-title":"High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa","volume":"8","author":"Manasa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.023_bib0005","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/QAI.0b013e3182557785","article-title":"Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa","volume":"60","author":"Fox","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2021.10.023_bib0006","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3851\/IMP1819","article-title":"Early outcomes and the virologic impact of delayed treatment switching on second-line therapy in an antiretroviral roll-out program in South Africa","volume":"16","author":"Levison","year":"2011","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2021.10.023_bib0007","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4102\/sajhivmed.v18i1.696","article-title":"Delays in switching patients onto second-line antiretroviral treatment at a public hospital in eThekwini, KwaZulu-Natal","volume":"18","author":"Narainsamy","year":"2017","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.jgar.2021.10.023_bib0008","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/cid\/cir729","article-title":"Immunologic criteria are poor predictors of virologic outcome: implications of HIV treatment monitoring in resource-limited settings","volume":"53","author":"Rawizza","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0009","doi-asserted-by":"crossref","first-page":"ofx233","DOI":"10.1093\/ofid\/ofx233","article-title":"Implication of first-line antiretroviral therapy choice on second-line options","volume":"4","author":"Meloni","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1086\/600044","article-title":"High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings","volume":"49","author":"Kumarasamy","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2016-000227","article-title":"UNAIDS 90-90-90 targets to end the AIDS epidemic by 2020 are not realistic: comment on \u2018Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades","volume":"2","author":"Bain","year":"2017","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.jgar.2021.10.023_bib0012","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/QAD.0b013e3283333639","article-title":"Outcomes after virologic failure of first-line ART in South Africa","volume":"24","author":"Murphy","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2021.10.023_bib0013","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/QAI.0b013e318228667f","article-title":"Drug resistance and viral tropism in HIV-1 subtype C-infected patients in KwaZulu-Natal, South Africa: implications for future treatment options","volume":"58","author":"Singh","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2021.10.023_bib0014","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e328356886d","article-title":"High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen","volume":"26","author":"Sunpath","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2021.10.023_bib0015","series-title":"National consolidated guidelines for the management of HIV in adults, adolescents, children and infants and prevention of mother-to-child transmission","year":"2020"},{"key":"10.1016\/j.jgar.2021.10.023_bib0016","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"66","author":"Stockdale","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0017","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/infdis\/jiw491","article-title":"Prevalence of antiretroviral drug resistance in patients who are not responding to protease inhibitor-based treatment: results from the first national survey in South Africa","volume":"214","author":"Steegen","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0018","series-title":"HIV impact assessment summary report","article-title":"The Fifth South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017","year":"2018"},{"key":"10.1016\/j.jgar.2021.10.023_bib0019","series-title":"National consolidated guidelines for prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults","year":"2015"},{"key":"10.1016\/j.jgar.2021.10.023_bib0020","first-page":"51242","article-title":"An affordable HIV-1 drug resistance monitoring method for resource limited settings","author":"Manasa","year":"2014","journal-title":"J Vis Exp"},{"key":"10.1016\/j.jgar.2021.10.023_bib0021","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0022","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4102\/sajhivmed.v18i1.776","article-title":"Adult antiretroviral therapy guidelines 2017","volume":"18","author":"Meintjes","year":"2017","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.jgar.2021.10.023_bib0023","article-title":"Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir\/r-containing antiretroviral therapy in South Africa","volume":"2011","author":"Wallis","year":"2011","journal-title":"AIDS Res Treat"},{"key":"10.1016\/j.jgar.2021.10.023_bib0024","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","article-title":"Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting","volume":"56","author":"Van Zyl","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2021.10.023_bib0025","doi-asserted-by":"crossref","first-page":"e32144","DOI":"10.1371\/journal.pone.0032144","article-title":"Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa","volume":"7","author":"Levison","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.023_bib0026","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/tmi.12741","article-title":"Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa","volume":"21","author":"Fox","year":"2016","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.jgar.2021.10.023_bib0027","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fmicb.2020.00438","article-title":"Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa","volume":"11","author":"Obasa","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2021.10.023_bib0028","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000001923","article-title":"A clinical prediction rule for protease inhibitor resistance in patients failing second-line antiretroviral therapy","volume":"80","author":"Cohen","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2021.10.023_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133452","article-title":"Factors associated with the development of drug resistance mutations in HIV-1 infected children failing protease inhibitor-based antiretroviral therapy in South Africa","volume":"10","author":"Rossouw","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.023_bib0030","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12879-021-05905-2","article-title":"Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa","volume":"21","author":"Obasa","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0031","doi-asserted-by":"crossref","first-page":"e21661","DOI":"10.1097\/MD.0000000000021661","article-title":"High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia","volume":"99","author":"Jordan","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jgar.2021.10.023_bib0032","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1093\/cid\/ciy589","article-title":"Evolution of protease inhibitor resistance in human immunodeficiency virus type 1 infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomized trial","volume":"68","author":"Thompson","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0033","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/s12879-017-2680-6","article-title":"Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda","volume":"17","author":"Ssempijja","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0034","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/QAD.0000000000002234","article-title":"Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure","volume":"33","author":"Shroufi","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2021.10.023_bib0035","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/aje\/kwaa049","article-title":"The impact of delayed switch to second-line antiretroviral therapy on mortality, depending on definition of failure time and CD4 count at failure","volume":"189","author":"Bell-Gorrod","year":"2020","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jgar.2021.10.023_bib0036","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/aid.2007.0127","article-title":"Genotypic susceptibility scores and HIV type 1 RNA responses in treatment-experienced subjects with HIV type 1 infection","volume":"24","author":"Anderson","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.jgar.2021.10.023_bib0037","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12981-018-0196-9","article-title":"Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa","volume":"15","author":"Evans","year":"2018","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jgar.2021.10.023_bib0038","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QAI.0000000000001883","article-title":"Third-line antiretroviral therapy program in the South African public sector: cohort description and virological outcomes","volume":"80","author":"Moorhouse","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2021.10.023_bib0039","doi-asserted-by":"crossref","first-page":"e61436","DOI":"10.1371\/journal.pone.0061436","article-title":"Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response","volume":"8","author":"Vercauteren","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.023_bib0040","doi-asserted-by":"crossref","first-page":"e11505","DOI":"10.1371\/journal.pone.0011505","article-title":"Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time","volume":"5","author":"Frentz","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.023_bib0041","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/infdis\/jiz650","article-title":"Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naive individuals: a systematic review of detection methods, prevalence, and clinical impact","volume":"221","author":"Mbunkah","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.023_bib0042","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1089\/aid.2014.0349","article-title":"Genetic changes in HIV-1 Gag-protease associated with protease inhibitor-based therapy failure in pediatric patients","volume":"31","author":"Giandhari","year":"2015","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:03:20Z","timestamp":1761991400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":42,"alternative-id":["S2213716521002496"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.023","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-1 drug resistance in adults and adolescents on protease inhibitor-based antiretroviral therapy in KwaZulu-Natal Province, South Africa","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}